Marathon Capital Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Marathon Capital Management’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-55,000	Closed	-$179K	–	99
2016 Q3	$179K	Hold	55,000	–	–	0.09%	77
2016 Q2	$184K	Hold	55,000	–	–	0.09%	69
2016 Q1	$134K	Buy	+55,000	New	+$130K	0.07%	75
2015 Q4	–	Sell	-55,000	Closed	-$189K	–	95
2015 Q3	$189K	Hold	55,000	–	–	0.1%	74
2015 Q2	$73K	Hold	55,000	–	–	0.03%	92
2015 Q1	$46K	Hold	55,000	–	–	0.02%	91
2014 Q4	$22K	Buy	55,000 +25,000	+83%	+$53.3K	0.02%	87
2014 Q3	$131K	Hold	30,000	–	–	0.12%	80
2014 Q2	$149K	Sell	30,000 -9,100	-23%	-$46.9K	0.12%	78
2014 Q1	$213K	Sell	39,100 -2,550	-6%	-$14.8K	0.16%	72
2013 Q4	$253K	Sell	41,650 -51,050	-55%	-$348K	0.18%	62
2013 Q3	$614K	Hold	92,700	–	–	0.53%	36
2013 Q2	$470K	Buy	+92,700	New	+$470K	0.4%	43

Other funds holding NYMX

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BAS

Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Marathon Capital Management's NYMX Position: Q4 2016 in Review

Marathon Capital Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2016, closing a stake of 55,000 shares — an estimated $179K sold.

Marathon Capital Management first reported a position in NYMX in Q2 2013 and held it in 13 quarters. The position peaked at $614K in Q3 2013. 29 funds tracked by Wall St. Rank hold NYMX as of Q4 2016.

Marathon Capital Management reported no remaining Nymox Pharmaceutical Corp position as of Q4 2016 after selling out during the quarter.
Marathon Capital Management sold 55,000 Nymox Pharmaceutical Corp shares in Q4 2016, an estimated $179K.
Marathon Capital Management first reported a position in Nymox Pharmaceutical Corp in Q2 2013 and held it in 13 quarters.
Marathon Capital Management's Nymox Pharmaceutical Corp position peaked at $614K in Q3 2013.
29 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2016.

Based on Marathon Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.